Roflumilast : the new orally active, selective phophodiesterase-4 inhibitor, for the treatment of COPD. (Q38137141)

29 August 2017

Roflumilast : the new orally active, selective phophodiesterase-4 inhibitor, for the treatment of COPD. (English)

1 reference

29 August 2017

Donald P Tashkin

1

1 reference

PubMed ID

24032576

29 August 2017

language of work or name

English

0 references

publication date

14 September 2013

1 reference

Expert Opinion on Pharmacotherapy

29 August 2017

1 reference

29 August 2017

15

1 reference

29 August 2017

85-96

1 reference

29 August 2017

1

1 reference

Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis

29 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.837159

Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.837159

Chronic obstructive pulmonary disease phenotypes: the future of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.837159

Genetic epidemiology of COPD (COPDGene) study design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.837159

Toward a consensus definition for COPD exacerbations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.837159

Exacerbations of chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.837159

Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.837159

Time course of recovery of health status following an infective exacerbation of chronic bronchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.837159

Factors affecting survival of hospitalised patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.837159

Lung function impairment, COPD hospitalisations and subsequent mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.837159

Acute exacerbations of COPD in the United States: inpatient burden and predictors of costs and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.837159

Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.837159

Effect of roflumilast on inflammatory cells in the lungs of cigarette smoke-exposed mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.837159

Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.837159

Roflumilast N-oxide, a PDE4 inhibitor, improves cilia motility and ciliated human bronchial epithelial cells compromised by cigarette smoke in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.837159

Effect of the phosphodiesterase 4 inhibitor roflumilast on glucose metabolism in patients with treatment-naive, newly diagnosed type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.837159

Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.837159

Roflumilast attenuates pulmonary inflammation upon segmental endotoxin challenge in healthy subjects: a randomized placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.837159

Roflumilast--an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.837159

Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.837159

Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.837159

Outcomes for COPD pharmacological trials: from lung function to biomarkers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.837159

The MCID of the transition dyspnea index is a total score of one unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.837159

Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.837159

Efficacy of roflumilast in the COPD frequent exacerbator phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.837159

Efficacy and safety of roflumilast in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.837159

PDE4 in the human heart - major player or little helper?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.837159

The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.837159

Cost-effectiveness of roflumilast in combination with bronchodilator therapies in patients with severe and very severe COPD in Switzerland

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.837159

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.837159

Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.837159

Pharmacologic treatments for chronic obstructive pulmonary disease: a mixed-treatment comparison meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.837159

The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.837159

A 4-year trial of tiotropium in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.837159

Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.837159

Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.837159

Inhaler mishandling remains common in real life and is associated with reduced disease control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.837159

Inhaler device selection: special considerations in elderly patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.837159

Novel antiinflammatory therapies for COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.837159

Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.837159

Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.837159

Effect of 1-Year Treatment with Roflumilast in Severe Chronic Obstructive Pulmonary Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.837159

10.1517/14656566.2013.837159

21 January 2018

Identifiers

DOI

1 reference

29 August 2017

1 reference

PubMed ID

24032576